On July 10, 2026, FDA issued a proposed rule that would modernize drug manufacturing registration requirements. If finalized, the rule would create a streamlined registration pathway for distributed manufacturing establishments operating under a hub-and-spoke model. FDA also says the rule would clarify registration requirements for certain foreign establishments that manufacture drugs, including active pharmaceutical ingredients (APIs), that indirectly enter the U.S. drug supply.

At first glance, this may sound like an administrative update. But for drug manufacturers, this is really about something bigger: visibility, traceability, and quality oversight in a more complex manufacturing environment.

What FDA is proposing

FDA describes distributed manufacturing as a model where a central quality oversight “hub” manages multiple equivalent manufacturing “spokes” at different locations. Currently, each manufacturing unit in that network generally registers separately. Under the proposed rule, a distributed manufacturing establishment could register as a single establishment, with units added, relocated, or removed through a streamlined update process.

FDA also notes that manufacturers would need to notify the agency in advance of unit relocation. That is important because it gives FDA a clearer, more current picture of where manufacturing is happening and how the network is changing.

The second major piece of the proposed rule focuses on foreign drug manufacturing establishments. FDA says some foreign establishments that manufacture drugs or drug comdonents only for distribution to other foreign establishments may not currently be registered with FDA, limiting the agency’s visibility into upstream supply chains. The proposed rule would clarify when those establishments must register and report the drugs they produce.

Why this matters for Quality

The hub-and-spoke model may reduce administrative burden, but it does not reduce quality responsibility.

If multiple manufacturing units operate as one establishment, the quality system has to prove that the units are truly operating under consistent oversight. That means the central hub cannot just be a coordination point. It must be able to demonstrate control.

For quality teams, the key questions become:

• Are procedures standardized across all units?
• Are deviations, CAPA, complaints, and change controls managed consistently?
• Are equipment, utilities, materials, and process controls equivalent where they need to be?
• Is data integrity maintained across systems and locations?
• Can the company trace where each manufacturing step occurred and who was responsible?
• Does the central quality unit have real authority over the full network?

These are the kinds of questions that can quickly become inspection issues if the operating model is not clearly documented.

Supply chain visibility is part of the same story

The foreign establishment portion of the proposed rule is also significant. FDA is clearly focused on improving visibility into upstream drug supply sources, including APIs and other components that may indirectly enter the U.S. market.

For manufacturers, this reinforces the need for strong supplier quality systems. It is not enough to know your direct supplier. Companies need to understand where critical materials originate, how upstream changes are communicated, and whether supplier qualification activities reflect actual risk.

In practice, this means supplier files, quality agreements, material specifications, change notification requirements, and audit strategies should all support a clear traceability story.

What companies should do now

Even though this is still a proposed rule, the direction is clear: FDA wants registration systems to better reflect modern manufacturing and to give the agency greater visibility into the drug supply chain.

Companies using, building, or considering distributed manufacturing models should start pressure-testing their quality systems now.

1) Map the manufacturing network

Identify every unit, site, supplier, contractor, and material flow involved in the product lifecycle. Be clear about which activities happen where and who owns each quality decision.

2) Define central quality oversight

Document how the hub exercises authority over the spokes. This should include deviation management, CAPA, complaints, change control, batch disposition, training, supplier oversight, and management review.

3) Standardize where consistency matters

Distributed units should not drift into site-by-site interpretation. Core procedures, acceptance criteria, documentation practices, and escalation pathways should be consistent and controlled.

4) Strengthen change control across locations

Adding, relocating, or removing a unit should trigger a defined change control process. The impact assessment should cover validation, equipment, personnel, materials, data systems, supplier controls, and regulatory reporting.

5) Build traceability into the documentation

FDA’s message is partly about knowing where drugs and components come from. Your documentation should make that easy to demonstrate, from API source to finished product release.

A practical readiness checklist

Before adopting or expanding a distributed manufacturing model, ask:

• Can we clearly define the hub-and-spoke structure?
• Does the central quality unit have documented authority?
• Are critical procedures standardized across units?
• Are deviations, CAPA, complaints, and change controls visible across the network?
• Can we trace product, material, and data flows across sites?
• Are supplier and API sources fully understood?
• Do quality agreements include change notification and escalation expectations?
• Are systems ready to support inspection requests across multiple locations?

Bottom line

FDA’s proposed registration rule is not just about making registration more efficient. It is about aligning regulatory oversight with the way drug manufacturing is evolving.

For manufacturers, the opportunity is to modernize without losing control. Distributed manufacturing can create flexibility and efficiency, but only if the quality system is strong enough to manage the network.

If your organization is building, expanding, or relying on a distributed manufacturing model, QSN can help pressure-test your quality oversight structure, supplier controls, change management, and inspection-readiness documentation before gaps become regulatory risk.